Normal view MARC view ISBD view

Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects

In Journal of Cancer Research and Therapeutics
Contributor(s): Jain V | Kalia VK | Tripathi RP | Mohanti BK | Vishwanath PN | Jalali R | Venkataramana NK | Sarin R | Banerji AK | Singh D | bsd@inmas.org | Dwarakanath BS.
Material type: materialTypeLabelArticleSeries: Vol 5 Issues Suppl.1.Publisher: 2009Description: S21-S26.Subject(s): 2-deoxy-D-glucose | quality of life | safety and tolerance | radiosensitization | hypofractionated radiotherapy | Glioblastoma multiforme | DDC classification: Online resources: Click here to access online In: Journal of Cancer Research and TherapeuticsSummary: Higher rates of glucose usage generally correlate with poor prognosis in several types of malignant tumours. Experimental studies (both in vitro and in vivo) have shown that 2-deoxy-D-glucose (2-DG), a glucose analog and glycolytic inhibitor, enhances radiation-induced damage selectively in tumor cells while protecting normal cells, thereby suggesting that 2-DG can be used as a differential radiomodifier to improve the efficacy of radiotherapy. Clinical trials undertaken to study the feasibility, safety, and validity of this suggested approach will be described. Based on 2-DG-induced radiosensitization observed in primary organ cultures of cerebral glioma tissues, clinical trials were designed taking into consideration the radiobiology of gliomas and pharmacokinetics of 2-DG. Phase I/II clinical trials have unequivocally demonstrated that a combination of 2-DG (200-300 mg 2-DG per kg body weight orally administered after overnight fasting, 20min before irradiation) with large weekly fractions (5 Gy/fraction
List(s) this item appears in: Jain PN
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR9812

Higher rates of glucose usage generally correlate with poor prognosis in several types of malignant tumours. Experimental studies (both in vitro and in vivo) have shown that 2-deoxy-D-glucose (2-DG), a glucose analog and glycolytic inhibitor, enhances radiation-induced damage selectively in tumor cells while protecting normal cells, thereby suggesting that 2-DG can be used as a differential radiomodifier to improve the efficacy of radiotherapy. Clinical trials undertaken to study the feasibility, safety, and validity of this suggested approach will be described. Based on 2-DG-induced radiosensitization observed in primary organ cultures of cerebral glioma tissues, clinical trials were designed taking into consideration the radiobiology of gliomas and pharmacokinetics of 2-DG. Phase I/II clinical trials have unequivocally demonstrated that a combination of 2-DG (200-300 mg 2-DG per kg body weight orally administered after overnight fasting, 20min before irradiation) with large weekly fractions (5 Gy/fraction

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha